Sarah Bettigole

This inventor holds 17 USPTO granted patents and 9 published patent applications and 5 EPO patents, primarily in Small Molecule Inhibitors. Top assignees: Cornell University, Volastra Therapeutics, Inc., Quentis Therapeutics, Inc.. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sarah Bettigole. Retrieved from https://idiyas.com/inventor/sarah-bettigole

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 9)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 20(Granted Patents)

Company Filing History:

Volastra Therapeutics, Inc.

patents

1 out of 1

Quentis Therapeutics, Inc.

patent

Years Active: 2018-2025

Loading Chart...

Areas of Expertise:

IRE1 Inhibitors

ENPP1 Inhibitors

Fibrosis Treatment

Immune Response

Small Molecules

Heterocyclic Compounds

Imino Sulfanones

Activation Agents

Biochemical Inhibition

Therapeutic Agents

Pharmaceutical Development

Targeted Therapy

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479818 - Treatment of fibrosis with IRE1 small molecule inhibitors (2025-11-25),

2. 12404248 - IRE1 small molecule inhibitors (2025-09-02),

3. 12091412 - Heterocyclic inhibitors of ENPP1 (2024-09-17),

4. 12071426 - IRE1 small molecule inhibitors (2024-08-27),

5. 12071424 - IRE1 small molecule inhibitors (2024-08-27),

6. 11945784 - IRE1 small molecule inhibitors (2024-04-02),

7. 11780849 - Imino sulfanone inhibitors of ENPP1 (2023-10-10),

8. 11649224 - IRE1 small molecule inhibitors (2023-05-16),

9. 11634403 - IRE1 small molecule inhibitors (2023-04-25),

10. 11021466 - IRE1 small molecule inhibitors (2021-06-01),

11. 10988461 - Small molecule IRE1-α inhibitors (2021-04-27),

12. 10961218 - IRE1 small molecule inhibitors (2021-03-30),

13. 10934275 - IRE1 small molecule inhibitors (2021-03-02),

14. 10745379 - IRE1 small molecule inhibitors (2020-08-18),

15. 10392367 - IRE1 small molecule inhibitors (2019-08-27),

Title: Sarah Bettigole: Innovator in Cancer Treatment

Introduction

Sarah Bettigole is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of small molecule inhibitors. With a total of 17 patents to her name, Bettigole is recognized for her groundbreaking work in targeting specific protein families involved in cancer progression.

Latest Patents

Among her latest patents, Bettigole has developed IRE1 small molecule inhibitors. These inhibitors target the IRE1 protein family members, providing methods for treating or ameliorating cancer in subjects. The inhibitors can be used for both solid and hematologic cancers. Another notable patent involves heterocyclic inhibitors of ENPP1, which relates to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). This patent details triazolopyrimidine and imidazolopyrimidine inhibitors and their applications in treating diseases mediated by ENPP1.

Career Highlights

Bettigole has worked with esteemed institutions such as Cornell University and Volastra Therapeutics, Inc. Her work has been pivotal in advancing the understanding and treatment of cancer through innovative therapeutic approaches.

Collaborations

Throughout her career, Bettigole has collaborated with notable colleagues, including Joseph P. Vacca and Dansu Li. These collaborations have further enhanced her research and contributed to her success in the field.

Conclusion

Sarah Bettigole stands out as a leading inventor in the realm of cancer treatment, with her innovative patents and collaborations paving the way for future advancements. Her dedication to research continues to impact the medical community positively.

Profile summary based on public USPTO records.